PR Archives – Page 4 of 4 – Seroba Lifesciences

Medtech

Quanta SC+ confirmed as safe and easy to use

Seroba’s portfolio company, Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a pioneering medical technology company developing a personal haemodialysis system (SC+) for patient use in the clinic and the home, today announced that results from its human factors testing (HFT) of SC+ have been published in Hemodialysis International, a leading peer-reviewed journal for the renal community. SC+ was designed …

Therapeutics

Fusion Raises $105m in Series B Financing

Seroba’s portfolio company, Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced the completion of a $105 million Series B financing led by Varian and new investor OrbiMed Advisors. Seroba participated in the round alongside new investors including Perceptive Advisors, Pivotal bioVenture Partners, and Rock Springs Capital, and the existing group of leading international …

Therapeutics

February 19, 2019

First Patient Dosed in Fusion Phase I trial

Seroba portfolio company, Fusion Pharmaceuticals, a biopharmaceutical company focused on radiotherapeutics (targeted alpha therapeutics) has announced the first patient was dosed in a Phase 1, first-in-human clinical trial of lead product candidate [225Ac]-FPI-1434 in patients with advanced solid tumors. “The entire Fusion team takes tremendous pride in having developed a new targeted alpha therapeutic and in moving it from the …

Medtech

January 30, 2019

Labcyte Sold to Beckman Coulter

Seroba portfolio company, Labcyte, has been acquired by Beckman Coulter Life Sciences, part of the larger Danaher Corporation which generates approximately $6.5 billion in annual revenue. Labcyte is best known for its Echo® acoustic droplet ejection technology, which uses sound waves to transfer tiny amounts of liquid with unequalled speed and accuracy. This technology—the centerpiece of Labcyte’s Echo Liquid Handlers—enables …

Medtech

January 8, 2019

PQ Bypass Announces $60M Financing

Seroba’s portfolio company, PQ Bypass, Inc., a medical device company dedicated to advancing treatment options for patients with peripheral arterial disease (PAD), has entered into an agreement that provides for up to an aggregate of $60 million in equity financing, led by Deerfield Management. Joining the round are existing investors, including Seroba Life Sciences and MedTech Venture Partners. The financing …

Therapeutics

January 7, 2019

Atlantic Therapeutics Raise €28M in Series B Funding

Atlantic Therapeutics, the medical technology company developing garment-based pelvic floor muscle strengthening and nerve stimulation devices treating the cause of bladder leaks, has announced that it has closed €28 million in Series B funding to continue its rapid growth trajectory. Having recently gained FDA clearance for its INNOVO® therapy device, this latest round of funding will enable Atlantic Therapeutics to …

Medtech

December 14, 2018

Otsuka Medical Devices Acquires Veryan

Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), a 100% subsidiary of Otsuka Holdings Co., Ltd., and Veryan Medical Ltd. (“Veryan”) have announced the completion of the acquisition of Veryan by Otsuka Medical Devices through its UK subsidiary Otsuka Medical Devices UK Ltd. Veryan’s BioMimics 3D peripheral vascular stent received U.S. FDA approval on 4 October, 2018. Following the acquisition, …

Medtech

September 7, 2018

Novate Acquired By BTG for Up To $150m

TG plc (LSE:BTG) (BTG) and Seroba’s portfolio company, Novate, today announced the signing of a definitive agreement in which BTG has acquired Novate for a $20m upfront payment with additional potential milestones of up to $130m. Novate which is based in Galway has developed a novel blood filter device (“Sentry”) used as protection against highly dangerous pulmonary clots or embolisms. …

Therapeutics

Prexton Acquired by Lundbeck for up to €905m.

H. Lundbeck A/S (Lundbeck) and Seroba’s Investee Company, Prexton Therapeutics BV (Prexton), today announced the signing of a definitive agreement in which Lundbeck will acquire Prexton. Under the terms of the agreement, Lundbeck will pay EUR 100 million upfront plus EUR 805 million in development and sales milestones. By acquiring Prexton, Lundbeck will obtain global rights of foliglurax, which currently …